Biomarkers – Products

Azenta Life Sciences has selected Oxford, UK, a key European life sciences hub, as the location for its next GENEWIZ Multiomics and Synthesis Solutions site. The site will feature a new state-of-the-art genomics lab scheduled to open in early 2024.

In this interview, delve into the significance of measuring immune mediators with high sensitivity, revolutionizing our understanding of disease dynamics.

PlaqueTec announced that it has received the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approval to continue its BIOPATTERN trial following recruitment of the first ten patients with CAD.

AMSBIO announce the launch of a custom service providing access to a suite of powerful spatial biology multi-omics profiling tools.

This application note presents the latest electrophoretic solutions for a more rapid assessment of cfDNA samples and optimal biomarker discovery.

Encouraging preliminary data from the ongoing DIPG clinical study to be presented at the 2023 Society for Neuro-Oncology Annual Meeting in Vancouver.

New NGS assay delivers exceptional coverage, providing a rapid and highly sensitive means of investigating MRD in AML samples.

Xsphera Biosciences, is pleased to announce the formalization of a Memorandum of Understanding (MOU) with NEX-I, a Seoul-based pioneer in immune-oncology therapeutics.

Novel computational model accurately predicts significant irAEs in NSCLC patients based on proteomic profiling of one pre-treatment blood test.

Clinical Trial Application filed for combined drug targeting amyloid deposits associated with Alzheimer’s Disease.